GlaxoSmithKline has promoted Deborah Waterhouse to replace ViiV Healthcare’s CEO Dominique Limet when he steps down from the HIV-focused firm at the end of March.
Limet has served as ViiV’s CEO since its 2009 formation as a partnership between GSK and Pfizer, with Shionogi subsequently joining the venture in 2012.
He said: “Establishing and then leading ViiV Healthcare for the past seven years has been an incredible honour and extremely fulfilling personally. I have had the pleasure to work with an exceptional team and am proud of how the business has grown to its current position as a leader in HIV therapy.
“We have delivered scientific innovation, while listening and better understanding the needs of people living with HIV, allowing us to both do good and do well as a business.”
Waterhouse, who is currently senior VP of primary care within GSK’s US pharmaceuticals business will take up a CEO designate role at ViiV in January, when she will be replaced by the company’s VP of US primary care sales Cheryl MacDiarmid.